Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C
NCT01899092
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C
Interventions
DRUG:
TT-034
Sponsor
Tacere Therapeutics, Inc.